Xencor, Inc.

Xencor, Inc. is a clinical-stage biopharmaceutical company that focuses on discovering and developing engineered antibodies for the treatment of cancer and autoimmune diseases. Its marketed products include Ultomiris, used for atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder, and Monjuvi, for relapsed or refractory diffuse large B-cell lymphoma. The company also has a robust pipeline of candidates in various stages of development, such as XmAb819 for renal cell carcinoma, XmAb541 for ovarian cancer, XmAb808 targeting a broadly expressed tumor antigen, and XmAb942 for Crohn's disease and ulcerative colitis. Additionally, it develops bispecific T-cell engagers like Plamotamab for rheumatoid arthritis and Xaluritamig for prostate cancer, along with other candidates for autoimmune diseases, hepatitis Delta, and HIV.

Xencor, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol XNCR. The trading currency for its shares is the US Dollar (USD). As a US-based company, its stock is traded in the United States, and investors typically use USD to buy and sell shares on the Nasdaq exchange.

Xencor, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. This means the company is involved in using biological processes and organisms to develop therapies, particularly engineered antibodies for serious diseases. As a biotechnology firm, Xencor focuses on research and development of innovative treatments for cancer and autoimmune conditions, leveraging its proprietary XmAb technology platform to create next-generation antibody-based medicines.

Xencor, Inc. is headquartered in the United States, as indicated by its country of incorporation. The company serves global markets, with its products and pipeline candidates targeting patients with cancer and autoimmune diseases worldwide. While specific headquarters location details are not provided in the data, its US base allows it to operate within the large American healthcare market and collaborate internationally. The company's marketed drugs, such as Ultomiris and Monjuvi, are available to patients in various regions, and its clinical trials for candidates like XmAb819 and XmAb541 are conducted globally to address unmet medical needs.

Xencor's key marketed products include Ultomiris, approved for atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder, and Monjuvi, for relapsed or refractory diffuse large B-cell lymphoma. Its pipeline features several promising candidates: XmAb819 (bispecific antibody for renal cell carcinoma), XmAb541 (Phase I for ovarian cancer), XmAb808 (bispecific targeting a tumor antigen), XmAb942 (for Crohn's disease and ulcerative colitis), Plamotamab (bispecific T-cell for rheumatoid arthritis), and Xaluritamig (bispecific T-cell engager for prostate cancer). Additionally, it develops ASP2138 for gastric and pancreatic cancers, JNJ-9401 for metastatic castration-resistant prostate cancer, Obexelimab for autoimmune diseases, Tobevibart for chronic hepatitis Delta, Zaltenibart for paroxysmal nocturnal hemoglobinuria, and Teropavimab/zinlirvimab for HIV. These reflect a diverse portfolio addressing oncology, autoimmune, and infectious diseases.